LVZPF
+0.0 · +0.00%
USD · PINK

Livzon Pharmaceutical Group Inc(LVZPF) Stock Analysis | Healthcare

USD --+0.00%
Reward61Moderate
Risk17Low
75%Data
Strong 18% profit margin · 21.1% dividend yield
Dividend King
Market Cap:4.63Bn
ⓘ
Reward Rating
61
Moderate
Reward Assessment
75% data coverage
Top 50% of stocksView factors
ⓘ
Risk Rating
17
Low
Risk Assessment

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on LVZPF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for LVZPF, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Livzon Pharmaceutical Group Inc?

researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally.

LVZPF · Verdict

Solid reward · low risk

LVZPF scores well on cash flow and balance sheet with no major weaknesses flagged in the model.

Based on 88% data coverage

LVZPF · Verdict

What’s working & what to watch

Strengths 5

  • Cash flow91/100

    20% free-cash-flow margin

  • Balance sheet89/100

    Interest covered 32.7×

  • Profitability82/100

    17% net margin · 16% ROE

  • Volatility80/100

    Top decile vs peers

  • Valuation75/100

    Above average

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Livzon Pharmaceutical Group Inc?

researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate and perospirone hydrochloride tablets for the psychiatric and neurological field; and shenqi fuzheng injection and anti-viral granules for the traditional Chinese medicine field. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 4.63B, and a P/E ratio of 15.4x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: Moderate (61)

The scoring profile indicates moderate reward potential, with profitability and valuation as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Drug Manufacturers - Specialty & Generic names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Market Cap4.63B
P/E Ratio15.3529
Dividend Yield21.07%
Beta0.37
Insider Activity
12M windowNo data
No insider activity data available for this ticker.